Corgenix Med Corp: (OTC: CONX)
$0.22
-0.01 (-4.35%)
Volume 3,370
May 20 03:37 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.19 - 0.22 |
| 52wk Low - High | 0.08 - 0.25 |
| Previous Close | 0.23 |
| Avg. Volume | 25,811 |
| Industry | MED PRODUCTS |
| Market Cap | 11.46 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.49 |
| PE (Forward) | 23.00 |
| Current Year Est. | 0.01 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 23.00 |
| PEG Ratio | NA |
| Current Year Est. | 0.01 |
| Current Quarter Estimate | 0.00 |
| Most Accurate Estimate | NA |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 09-26-2013 |
| EPS Last Year | -0.01 |
| Expected Earnings Growth | NA |
Company Description
CORGENIX is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CORGENIX MEDICL | CONX | 0.23 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
| BIO-RAD LABS -A | BIO | 116.02 | |
|
| BIOLIFE SOL INC | BLFS | 0.31 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Q2: Strong Revenue, Another Profitable Quarter
Feb 19, 2013
Q1: Record Revenue and Income. Int'l Sales Growing Is Huge Positive
Nov 14, 2012
Strong 2013 Guidance. Moving Price Target Up To $0.60/share
Oct 01, 2012
Q4 Revenue Guidance Revised Upwards
Jul 05, 2012
Report Not Available
Financials
| EPS TTM | -0.01 |
| Sales | 9 |
| Net Income | 0 |
| Price/Earnings | NA |
| Price/Book | 2.14 |
| Price/Cash Flow | NA |
| Price/Sales | 1.13 |
News
Corgenix Medical receives CE mark for antigen diagnostic test for Lassa fever - Datamonitor
May 20, 2013
Corgenix Reports Third Quarter Fiscal 2013 Financial Results - Businesswire
May 14, 2013
Corgenix Medical expands contract services business unit - Datamonitor
May 13, 2013
Corgenix Gets CE Mark for ReLASV Antigen Rapid Test for Diagnosis of Lassa Fever - Close-Up Media
May 10, 2013
Corgenix Bolsters Contract Services Business Unit - Close-Up Media
May 8, 2013
Corgenix Schedules Conference Call to Discuss 3rd Quarter Results - Close-Up Media
May 8, 2013
Broomfield-based Corgenix receives CE Mark for Lassa test - Mcclatchy-Tribune Information Services -- Unrestricted
May 7, 2013
Corgenix Bolsters Contract Services Business Unit - Close-Up Media
May 7, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 0.60 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 6 out of 72 |
